Aspirin and Colorectal Cancer Prevention: What the Latest Research Shows
For years, aspirin has been investigated as a potential preventative measure against colorectal cancer. However, a new comprehensive review published in the Cochrane Database of Systematic Reviews casts doubt on its reliability for most individuals. The analysis highlights that daily aspirin employ doesn’t offer a quick or dependable way to prevent bowel cancer and carries the immediate risk of serious bleeding.
The Cochrane Review Findings
Researchers at West China Hospital of Sichuan University in China analyzed data from 10 randomized controlled trials, encompassing over 124,837 participants. The review focused on whether aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) could prevent colorectal cancer or precancerous polyps (adenomas) in people at average risk. Notably, there were no suitable trials available to assess the effects of non-aspirin NSAIDs, meaning the conclusions apply specifically to aspirin.1
The review determined that aspirin likely provides little to no short-term benefit in reducing bowel cancer risk within the first 5 to 15 years of use. While some studies suggested a possible protective effect after more than 10-15 years, the certainty of this evidence was deemed very low.1 This potential long-term benefit stemmed from observational follow-up phases of trials, which are prone to bias due to factors like participants independently starting or stopping aspirin use.
Immediate Bleeding Risks Outweigh Uncertain Benefits
A significant finding of the review is the clear and immediate risk of serious bleeding associated with daily aspirin use. This risk exists even with low-dose aspirin.2 Researchers emphasize that any potential long-term cancer benefits must be carefully weighed against this well-established and immediate bleeding risk.3
“My biggest worry is that people might assume that taking an aspirin today will protect them from cancer tomorrow,” says Dr. Bo Zhang, a senior author of the study. “In reality, any potential preventive effect takes over a decade to appear, if it appears at all, while the bleeding risk begins immediately.”2
Who Might Still Benefit?
It’s significant to note that previous research has indicated aspirin may be beneficial for specific high-risk groups, such as individuals with Lynch syndrome, an inherited condition that significantly increases colorectal cancer risk. However, this latest review specifically focused on individuals at average risk, and the evidence for a protective effect in this population remains highly uncertain.2
The Importance of Individualized Prevention
The authors of the review strongly advise against initiating aspirin use for cancer prevention without first discussing personal bleeding risks with a healthcare professional.2 Dr. Dan Cao, another senior author, emphasizes the need to move away from a “one-size-fits-all” approach. “Widespread aspirin use in the general population simply isn’t supported by the evidence,” he states. “The future lies in precision prevention – using molecular markers and individual risk profiles to identify who might benefit most and who is most at risk.”2
Key Takeaways
- Daily aspirin is not a reliable method for preventing colorectal cancer in people at average risk.
- The potential benefits of aspirin for cancer prevention are uncertain and may seize over a decade to appear.
- Daily aspirin use carries an immediate risk of serious bleeding, even at low doses.
- Individuals considering aspirin for cancer prevention should consult with a healthcare professional to assess their personal risks and benefits.
The researchers conclude that the relationship between aspirin and cancer prevention is complex and requires a more nuanced understanding. As Dr. Zhang states, “Our rigorous analysis of the highest-quality trials reveals that the ‘aspirin for cancer prevention’ story is more complex than a simple ‘yes or no.’ The current evidence does not support a blanket recommendation for aspirin use purely to prevent bowel cancer.”2